Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation.

CONCLUSIONS: Inhibition of IgA aβ2GPI by DI is possible and can be enhanced by biochemical modification in a subset of patients.
PMID: 31126213 [PubMed - as supplied by publisher]

Source: Lupus - May 23, 2019 Category: Rheumatology Authors: Albay A, Artim-Esen B, Pericleous C, Wincup C, Giles I, Rahman A, McDonnell T Tags: Lupus Source Type: research